BioHarvest Sciences Inc. announced the registration of its common shares on the Tel Aviv Stock Exchange (TASE), achieving dual listing alongside its existing Nasdaq Capital Market listing. Trading on TASE commenced on September 8, 2026, under the symbol BHST. The company registered approximately 22.7 million outstanding shares for trading, along with up to 4.5 million additional shares available for future issuance under equity incentive plans and warrants. This expansion provides investors in Israel with direct access to the company's equity. BioHarvest Sciences Inc. operates in the biotechnology industry, focusing on the development of plant-based therapeutics.

BioHarvest Sciences Inc. announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) in addition to its existing Nasdaq listing. Trading on TASE is expected to begin on September 8, 2026, under the symbol BHST. The company registered approximately 22.7 million outstanding common shares for listing, along with up to 4.5 million shares available for future issuance under its Equity Incentive Plan and 610,742 shares issuable upon warrant exercise. This move aims to broaden investor access and strengthen ties with the Israeli investment community. BioHarvest Sciences operates in the biotechnology sector, specializing in botanical synthesis technology to develop plant-based therapeutic solutions and nutraceutical products.

BioHarvest Sciences Inc. reported second quarter 2026 financial results, posting $8.8 million in revenue, a 3.8% increase year-over-year, with a net loss of $3.7 million compared to $4.1 million in the prior period. The company secured its first CDMO manufacturing agreement for a rare botanical fragrance ingredient, supporting a planned 20-ton commercial production program over two years. BioHarvest also announced revised full-year guidance, lowering expected CDMO revenue to $4-$5 million and VINIA D2C revenue to $33-$35 million, while narrowing the consolidated EBITDA loss range to $3-$5 million. Additionally, the firm received a $1.4 million grant from the Israel Innovation Authority and advanced its saffron development program with SaffronTech. BioHarvest Sciences Inc. operates in the biotechnology industry, leveraging botanical synthesis technology for contract manufacturing services and consumer wellness products.

BioHarvest Sciences Inc. filed its unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026. The company reported revenues of $17,344 thousand for the first half of 2026, a 5.9% increase from $16,375 thousand in the prior year period. Net loss widened to $6,356 thousand from $6,418 thousand previously, driven by higher research and development expenses of $3,058 thousand and sales and marketing costs of $8,506 thousand. Gross margin remained stable at 58%. Cash and cash equivalents decreased to $15,211 thousand from $23,025 thousand at year-end 2025 due to operating losses and capital expenditures. The company continues to face substantial doubt regarding its ability to continue as a going concern due to historical operating losses and reliance on external financing. BioHarvest Sciences Inc. is a biotechnology company that utilizes Botanical Synthesis Platform Technology to produce plant-based active ingredients for nutraceutical, pharmaceutical, and cosmeceutical applications.